May 16, 2014

EDAP Highlights Its HIFU and Lithotripsy Technologies at 109th Annual AUA Meeting

Receives Outstanding Poster Designation for Ablatherm-HIFU

LYON, France, May 16, 2014 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced that its HIFU and lithotripsy technologies will be featured at the 109th Annual American Urology Association (AUA) Meeting that will be held in Orlando, FL on May 16 - 24, 2014.

Live demonstrations utilizing the Sonolith i-move will be conducted at the Company's booth #1961. Detailed discussions of EDAP's HIFU technology will take place during the scientific and educational sessions of the meeting including:

- A plenary session 'point-counter point' debate on HIFU for localized prostate cancer.
- An educational course dedicated to HIFU for prostate cancer being conducted by key opinion leaders.
- Five poster abstracts reporting clinical research outcomes by clinicians and scientists utilizing Ablatherm-HIFU.

Notably, one of the posters entitled "Radical Prostatectomy versus High Intensity Focused Ultrasound for localized prostate cancer: A Matched Pair Comparison" from Sebastien Crouzet and the research team at Edouard Herriot Hospital in Lyon France, has been officially recognized as "Outstanding Poster in Oncology".

Sebastien Crouzet, Urologist at Edouard Herriot Hospital, commented, "It is an honor that such an institution as AUA awards our studies and clinical work on HIFU versus radical prostatectomy as it is recognition of the scientific and clinical status of HIFU in the treatment of prostate cancer."

Marc Oczachowski, EDAP's Chief Executive Officer, said, "As the largest global urology meeting, the AUA is one of the key medical meetings for EDAP to present its HIFU and lithotripsy technologies and the advancements of its devices. This year's meeting will be of particular significance for the Company, as our HIFU technology will be highlighted in five poster presentations dedicated to Ablatherm-HIFU and its clinical outcomes. Also, it is indeed a strong recognition that HIFU technology is this year part of a specific educational course during AUA and that the Lyon's Edouard Herriot University hospital team has been rewarded for its outstanding comparative work on Ablatherm-HIFU."

About EDAP TMS SA

EDAP TMS SA markets today Ablatherm® for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment, Ablatherm-HIFU is approved and commercialized in Europe as a treatment for prostate cancer and is currently under regulatory review in the U.S. following submission of the Pre-Market Approval Application in February 2013 after the completion of a multi-center U.S. Phase II/III clinical trial under an Investigational Device Exemption (IDE) granted by the FDA. In February 2013, the Company introduced a new innovative HIFU device, the Focal One® dedicated to focal therapy of prostate cancer. Focal One® is CE marked but is not FDA approved. The Company also develops its HIFU technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment (the Sonolith® range) for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, and http://www.hifu-planet.com.

Forward-Looking Statements

In addition to historical information, this press release may contain forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results

anticipated in the forward-looking statements include, among others the uncertainties of the U.S. FDA approval process, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy device. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F. Ablatherm-HIFU treatment is in clinical trials, but not FDA-approved or marketed in the United States.

CONTACT: Blandine Confort

Investor Relations / Legal Affairs

EDAP TMS SA

+33 4 72 15 31 72

bconfort@edap-tms.com

Investors/Media:

Stephanie Carrington /David Burke/Aaron Estrada

The Ruth Group

646-536-7017/7009/7028

scarrington@theruthgroup.com

dburke@theruthgroup.com

aestrada@theruthgroup.com

Source: EDAP TMS SA